Page last updated: 2024-12-06
setastine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 43082 |
CHEMBL ID | 1742452 |
CHEBI ID | 135513 |
SCHEMBL ID | 30329 |
MeSH ID | M0152171 |
Synonyms (26)
Synonym |
---|
setastine |
CHEBI:135513 |
1-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]azepane |
c22h28clno |
AKOS016013928 |
6g3ocf528j , |
1-(2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)hexahydro-1h-azepine |
setastine [inn] |
1h-azepine, 1-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)hexahydro- |
setastinum |
64294-95-7 |
setastinum [inn-latin] |
unii-6g3ocf528j |
setastina [inn-spanish] |
CHEMBL1742452 |
1-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)azepane |
SCHEMBL30329 |
setastine [who-dd] |
setastine [mi] |
1h-azepine, 1-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]hexahydro- |
(r)-1-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)azepane |
FT-0719113 |
Q7456369 |
A914954 |
1-{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}azepane |
DTXSID30867067 |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
---|---|---|
"Setastine HCl has a long lasting (up to 16 h) antihistamine effect with a good oral effectiveness." | ( Pharmacology of the new H1-receptor antagonist setastine hydrochloride. Barthó, L; Kápolnai, L; Petöcz, L; Porszász, J; Porszász, KG; Szolscányi, J; Varga, F, 1990) | 1.26 |
"Setastine HCl has a long lasting (up to 16 h) antihistamine effect with a good oral effectiveness." | ( Pharmacology of the new H1-receptor antagonist setastine hydrochloride. Barthó, L; Kápolnai, L; Petöcz, L; Porszász, J; Porszász, KG; Szolscányi, J; Varga, F, 1990) | 1.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (42.86) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (28.57%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (71.43%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |